Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 26;16(1):192.
doi: 10.1186/s13195-024-01556-y.

Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study

Affiliations

Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study

Konstantina Sampani et al. Alzheimers Res Ther. .

Abstract

Background: Protein biomarkers have been broadly investigated in cerebrospinal fluid and blood for the detection of neurodegenerative diseases, yet a clinically useful diagnostic test to detect early, pre-symptomatic Alzheimer's disease (AD) remains elusive. We conducted this study to quantify Aβ40, Aβ42, total Tau (t-Tau), hyperphosphorylated Tau (ptau181), glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) in eye fluids relative to blood.

Methods: In this cross-sectional study we collected vitreous humor, aqueous humor, tear fluid and plasma in patients undergoing surgery for eye disease. All six biomarkers were quantitatively measured by digital immunoassay. Spearman and Bland-Altman correlation analyses were performed to assess the agreement of levels between ocular fluids and plasma.

Results: Seventy-nine adults underwent pars-plana vitrectomy in at least one eye. Of the 79, there were 77 vitreous, 67 blood, 56 tear fluid, and 51 aqueous samples. All six biomarkers were quantified in each bio-sample, except GFAP and NfL in tear fluid due to low sample volume. All six biomarkers were elevated in vitreous humor compared to plasma samples. T-Tau, ptau181, GFAP and NfL were higher in aqueous than in plasma, and t-Tau and ptau181 concentrations were higher in tear fluid than in plasma. Significant correlations were found between Aβ40 in plasma and tears (r = 0.5; p = 0.019), t-Tau in plasma and vitreous (r = 0.4; p = 0.004), NfL in plasma and vitreous (r = 0.3; p = 0.006) and plasma and aqueous (r = 0.5; p = 0.004). No significant associations were found for Aβ42, ptau181 and GFAP among ocular fluids relative to plasma. Bland-Altman analysis showed aqueous humor had the closest agreement to plasma across all biomarkers. Biomarker levels in ocular fluids revealed statistically significant associations between vitreous and aqueous for t-Tau (r = 0.5; p = 0.001), GFAP (r = 0.6; p < 0.001) and NfL (r = 0.7; p < 0.001).

Conclusion: AD biomarkers are detectable in greater quantities in eye fluids than in plasma and show correlations with levels in plasma. Future studies are needed to assess the utility of ocular fluid biomarkers as diagnostic and prognostic markers for AD, especially in those at risk with eye disease.

Keywords: Alzheimer’s disease; Amyloid beta; Aqueous humor; Glial fibrillary acidic protein; Neurofilament light chain; Tau; Tears; Vitreous humor.

PubMed Disclaimer

Conflict of interest statement

KS, SN, FTZ, NA, EES, XC, NHS, YT, TDS, MLS declare that they have no competing interests. MLA received a single time honorarium from the Michael J Fox Foundation for services unrelated to this study. MLA also receives royalties from Oxford University Press Inc.

Figures

Fig. 1
Fig. 1
Violin box plots for the distribution of the relative concentrations (pg/mL) of each biomarker among the different biofluids. Bottom and top lines of the boxes correspond to first and third quartiles respectively, and the middle lines refers to the mean value. The density plots represent an estimation that shows the distribution shape of the data and its bottom and top points correspond to the zero and fourth quartiles respectively. Aβ: amyloid beta; t-Tau: total tau; ptau181: hyperphosphorylated tau 181; GFAP: Glial fibrillary acidic protein; NfL: neurofilament light chain

References

    1. Alzheimer’s disease facts and figures. Alzheimers Dement. 2023;19(4):1598–695. 10.1002/alz.13016 - DOI - PubMed
    1. Collaborators, G.B.D.D.F. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105–25. 10.1016/S2468-2667(21)00249-8 - DOI - PMC - PubMed
    1. Hansson O, et al. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimers Dement. 2022;18(12):2669–86. 10.1002/alz.12756 - DOI - PMC - PubMed
    1. Teunissen CE, et al. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66–77. 10.1016/S1474-4422(21)00361-6 - DOI - PubMed
    1. Lee CS, et al. Associations between recent and established ophthalmic conditions and risk of Alzheimer’s disease. Alzheimers Dement. 2019;15(1):34–41. 10.1016/j.jalz.2018.06.2856 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources